Independent Pharmacy Cooperative, the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio

Cabaletta Bio, Inc. has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for CABA-201, an investigational therapy developed to treat idiopathic inflammatory myopathies

Ascendis Pharma A/S has declared the launch of YORVIPATH® in Germany and Austria. YORVIPATH is a parathyroid hormone replacement therapy designed for adults dealing with chronic hypoparathyroidism.

Lexaria Bioscience Corp. has officially submitted its Investigational New Drug application for the anticipated U.S. phase 1b hypertension clinical trial, HYPER-H23-1, featuring DehydraTECH-CBD

Synthekine Inc., a company specializing in engineered cytokine therapeutics, has recently announced a global collaboration with Sanofi to jointly develop and commercialize

Rise Therapeutics, a biotechnology company in the clinical stage, has successfully enrolled its initial participant in the Phase 1 clinical trial for R-2487, a prospective treatment for rheumatoid arthritis

Sionna Therapeutics, a life sciences company focused on advancing treatments for cystic fibrosis , has initiated a Phase 1 clinical trial for SION-109 after receiving approval for its Investigational New Drug

Cognito Therapeutics, a neurotechnology company specializing in the development of disease-modifying therapies for neurodegenerative diseases, has announced the enrollment of the first participant in a biomarker

Mercury Bio, a biotechnology company based in Santa Fe, NM, has recently become a charter member of the Alliance for mRNA Medicines, a notable global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics and vaccines

GC Biopharma Corp. has announced that the European Medicines Agency granted Orphan Drug Designation to GC1130A, an intracerebroventricular Enzyme Replacement Therapy